Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry G Grabowski

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2007
Economics of new oncology drug developmentJoseph A DiMasi, Henry G Grabowski
Health Affairs (Project Hope)|March 9, 2006
The quantity and quality of worldwide new drug introductions, 1982-2003Henry G Grabowski, Y Richard Wang
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Impact of economic, regulatory, and patent policies on innovation in cancer chemopreventionHenry G Grabowski, Jeffrey L Moe
Health Affairs (Project Hope)|June 4, 2014
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near futureHenry G Grabowski, Rahul Guha, Maria Salgado
Health Affairs (Project Hope)|February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovationHenry G Grabowski, Joseph A DiMasi, Genia Long
Health Affairs (Project Hope)|March 9, 2006
Developing drugs for developing countriesDavid B Ridley, Henry G Grabowski, Jeffrey L Moe
Journal of Health Politics, Policy and Law|March 8, 2008
Misleading congress about drug development: ReplyJoseph A Dimasi, Ronald W Hansen, Henry G Grabowski
Journal of Health Economics|February 28, 2003
The price of innovation: new estimates of drug development costsJoseph A DiMasi, Ronald W Hansen, Henry G Grabowski
Journal of Health Economics|March 2, 2016
Innovation in the pharmaceutical industry: New estimates of R&D costsJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
The New England Journal of Medicine|May 14, 2015
The cost of drug developmentJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2007
Economics of new oncology drug developmentJoseph A DiMasi, Henry G Grabowski
Health Affairs (Project Hope)|March 9, 2006
The quantity and quality of worldwide new drug introductions, 1982-2003Henry G Grabowski, Y Richard Wang
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Impact of economic, regulatory, and patent policies on innovation in cancer chemopreventionHenry G Grabowski, Jeffrey L Moe
Health Affairs (Project Hope)|June 4, 2014
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near futureHenry G Grabowski, Rahul Guha, Maria Salgado
Health Affairs (Project Hope)|February 4, 2015
The roles of patents and research and development incentives in biopharmaceutical innovationHenry G Grabowski, Joseph A DiMasi, Genia Long
Health Affairs (Project Hope)|March 9, 2006
Developing drugs for developing countriesDavid B Ridley, Henry G Grabowski, Jeffrey L Moe
Journal of Health Politics, Policy and Law|March 8, 2008
Misleading congress about drug development: ReplyJoseph A Dimasi, Ronald W Hansen, Henry G Grabowski
Journal of Health Economics|February 28, 2003
The price of innovation: new estimates of drug development costsJoseph A DiMasi, Ronald W Hansen, Henry G Grabowski
Journal of Health Economics|March 2, 2016
Innovation in the pharmaceutical industry: New estimates of R&D costsJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
The New England Journal of Medicine|May 14, 2015
The cost of drug developmentJoseph A DiMasi, Henry G Grabowski, Ronald W Hansen
Pageof 2